Login / Signup

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam.

Clara MukuriaTracey YoungAnju KeetharuthSimon BorghsJohn Brazier
Published in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2016)
EQ-5D-3L had weak-to-moderate correlations with QOLIE-31P and varied with QOLIE-31P severity groups, but showed less responsiveness than QOLIE-31P. Given this lack of sensitivity, EQ-5D-3L may not be appropriate for measuring the impact of interventions in cost-effectiveness analysis in this population and disease-specific preference-based measures may be more appropriate.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • double blind
  • physical activity
  • phase ii